Early Discontinuation of Empiric Antibiotics in Pediatric Haploidentical Hematopoietic Cell Transplant Recipients with Febrile Neutropenia

Clicks: 1
ID: 315036
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #494 of 531 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 531 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Febrile neutropenia (FN) is common in children, adolescents, and young adults (CAYA) undergoing hematopoietic cell transplant (HCT), particularly following allogeneic haploidentical HCT (haplo-HCT). Optimal empiric antibiotic duration for FN is not well established in this population. Methods A retrospective quasi-experimental study was conducted among CAYA undergoing haplo-HCT between 2010 and 2022 who experienced FN. In 2017 a guideline was implemented for discontinuation of empiric antibiotics within 72 hours of FN in patients without identified infection regardless of persistence of fever. We compared patients who underwent haplo-HCT pre-implementation (Pre-I) vs. post-implementation (Post-I) of this guideline. The primary outcome was days of therapy (DOT). Secondary outcomes included incidence of bloodstream infections (BSI), ICU admission, and mortality from 72 hours of FN onset until neutrophil engraftment. A Desirability of Outcome Ranking (DOOR) with a modified Response Adjusted for Duration of Antibiotic Risk (RADAR) approach using DOT was applied to comprehensively assess outcomes. Results Patients in Post-I (n=82) had fewer DOT compared to Pre-I (n=90) with a median difference of 8 days (p<0.01). There were no significant differences in BSI incidence, ICU admission, or mortality between groups. The DOOR-modified RADAR analysis demonstrated Post-I was associated with a 70% (95% CI = 61, 78%) probability of experiencing a more favorable clinical outcome compared to the Pre-I group (p <0.01). Conclusions Early antibiotic discontinuation appears safe and feasible in CAYA haplo-HCT recipients with FN, significantly reducing antibiotic exposure without increasing adverse outcomes. Large prospective multicenter trials are needed to confirm these findings.
Reference Key
openalex_W7162443685 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sandra Castejon‐Ramirez, Diego R. Hijano, Rachel L Wattier, Jose Ferrolino, M PETERSON, Pamela Merritt, Amber Davis, Amanda Cole, Kim J Alison, Ashleigh Gowen, Ronald Dallas, Li Tang, Jiaming Li, Brandon Triplett, Gabriela Maron
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag327
URL
https://doi.org/10.1093/cid/ciag327
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.